ReProgram Episode 14 The NAD Myth? What the New Human Data Really Say🧠 Episode Overview In this episode of The ReProgram, Dr. George Murphy takes a critical but balanced look at one of the most popular ideas in the longevity space:That NAD levels decline with age — and that boosting NAD may help slow aging.But new human data challenge one of the most common assumptions behind the NAD story:Whole-blood NAD levels may not decline with age.This episode explores what that finding means — and what it does not mean.The central takeaway:NAD is not dead.But the simplistic NAD longevity story needs a reset. 🔑 Keywords NAD, NAD+, aging, longevity, NR, NMN, NAD boosters, nicotinamide riboside, nicotinamide mononucleotide, mitochondrial function, DNA repair, sirtuins, PARPs, CD38, cellular metabolism, biological aging, healthspan, resilience, recovery capacity, inflammation, stress response, biomarker, whole-blood NAD, NAD decline, NAD supplements, NAD IV therapy, metabolism, cellular stress, anti-aging supplements, longevity science, The ReProgram Podcast 🧠 Takeaways • NAD is essential biology, but it should not be treated as a magic anti-aging molecule. • New human data challenge the idea that whole-blood NAD levels universally decline with age. • Raising blood NAD is not the same thing as proving that aging has slowed. • NAD biology is likely tissue-specific, disease-specific, stress-specific, and context-dependent. • Blood NAD is not necessarily a reliable window into NAD metabolism in muscle, brain, liver, immune cells, or other tissues. • NAD boosters like NR and NMN can raise NAD-related metabolites, but that does not automatically mean they improve healthspan or longevity. • The most honest current framing is that NAD boosters are biologically plausible, biomarker-active, and clinically unproven as general longevity therapies. • NAD may be more relevant in specific contexts of stress, disease, frailty, metabolic dysfunction, or impaired recovery than as a universal supplement for healthy people. • NAD infusions and high-cost wellness protocols deserve extra skepticism because the marketing often exceeds the evidence. • Longevity interventions should be judged by function, resilience, healthspan, and clinical outcomes — not by biomarker movement alone. 🎙️ The ReProgram PerspectiveNAD biology matters, but the public story has become too simple.The key question is not whether we can raise NAD. The key question is whether doing so improves function, resilience, recovery, disease risk, or healthspan.Blood biomarkers can be useful, but they are not outcomes. Aging biology is not a supplement slogan.The ReProgram lens is clear: mechanism over marketing, outcome data over anecdotes, and trade-offs over hype. Chapters 00:00 The NAD Longevity Story Just Changed 01:24 What NAD Is and Why It Matters 03:31 NAD as Cellular Currency 04:37 The Old Model: Aging, Inflammation, and NAD Decline 06:32 The New Human Data on Whole-Blood NAD 08:30 Why Blood NAD Is Not the Whole Story 11:01 NAD Boosters: What They May Actually Do 12:58 NAD Boosters remain Scientifically Interesting 14:39 NAD Boosters: Limitations 16:55 Should You Take NAD for Longevity? 19:28 The ReProgram Takeaway: NAD Is Not Dead, But the Hype Needs a Reset Notes: Nature Metabolism Paper: Human whole-blood NAD+ levels do not vary with age or lifestyle interventions: https://www.nature.com/articles/s42255-026-01537-5 Cell Metabolism Paper: NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00212-8
